GT Biopharma Inc (GTBP)

[conix]

GT Biopharma announces strong early-stage safety results for blood cancer therapy

Jun. 23, 2021

By: Dulan Lokuwithana, SA News Editor
Cancer cells

GT Biopharma (GTBP +6.0%) announced interim results from a Phase 1 trial for the company’s recombinant fusion protein conjugate, GTB-3550 in the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).

With 11 patients completing the treatment, GTB-3550 was well-tolerated with no cytokine release syndrome detected, the company said.

57% of patients were found to have a significant reduction in AML/MDS cancer cells at doses ranging from 25mcg/kg/day to 150mcg/kg/day. Some patients had a 63.7% reduction in bone marrow blast levels.

“In addition to strong safety results, we have seen significant reductions in CD33+ cancer cells in four of the last seven patients (57%) treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day,” noted GT Biopharma CEO, Anthony Cataldo.

In April, GT Biopharma announced the appointment of industry veteran and its former board member Gregory Berk as the new chief medical officer.